The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

Background RET rearrangements are found in 1–2% of non-small-cell lung cancers.
Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall …

Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are
driven by less common genomic alterations, registries provide complementary information …

Lung cancer continues to be a major global health problem; the disease is diagnosed in
more than 1.6 million new patients each year. However, significant progress is underway in …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

Introduction Although KRAS mutations in NSCLC have been considered mutually exclusive
driver mutations for a long time, there is now growing evidence that KRAS-mutated NSCLC …